Publicaciones en colaboración con investigadores/as de Hospital Universitario de Salamanca (19)

2022

  1. Safety and efficacy of ribociclib plus letrozole in patients with HR+, HER2– advanced breast cancer: Results from the Spanish sub-population of the phase 3b CompLEEment-1 trial

    Breast, Vol. 66, pp. 77-84

2021

  1. Health-related quality of life with palbociclib plus endocrine therapy versus capecitabine in postmenopausal patients with hormone receptor–positive metastatic breast cancer: Patient-reported outcomes in the PEARL study

    European Journal of Cancer, Vol. 156, pp. 70-82

2019

  1. Neoadjuvant Management of Early Breast Cancer: A Clinical and Investigational Position Statement

    Oncologist, Vol. 24, Núm. 5, pp. 603-611

2018

  1. Outcomes of single versus double hormone receptor–positive breast cancer. A GEICAM/9906 sub-study

    European Journal of Cancer, Vol. 94, pp. 199-205

2017

  1. New clinical trials regulation in Spain: analysis of royal decree 1090/2015

    Clinical and Translational Oncology, Vol. 19, Núm. 3, pp. 291-300

2016

  1. Prognostic ability of EndoPredict compared to research-based versions of the PAM50 risk of recurrence (ROR) scores in node-positive, estrogen receptor-positive, and HER2-negative breast cancer. A GEICAM/9906 sub-study

    Breast Cancer Research and Treatment, Vol. 156, Núm. 1, pp. 81-89

  2. SEOM Clinical Guideline for bone metastases from solid tumours (2016)

    Clinical and Translational Oncology, Vol. 18, Núm. 12, pp. 1243-1253

2015

  1. Epirubicin plus cyclophosphamide followed by docetaxel versus epirubicin plus docetaxel followed by capecitabine as adjuvant therapy for node-positive early breast cancer: Results from the GEICAM/2003-10 study

    Journal of Clinical Oncology, Vol. 33, Núm. 32, pp. 3788-3795

  2. SEOM Guidelines 2015: a new era in the collaboration with the Spanish Cancer Research Cooperative Groups

    Clinical and Translational Oncology

2014

  1. Clinical guide SEOM on venous thromboembolism in cancer patients

    Clinical and Translational Oncology, Vol. 16, Núm. 12, pp. 1079-1090

2013

  1. Fluorouracil, doxorubicin, and cyclophosphamide (FAC) versus FAC followed by weekly paclitaxel as adjuvant therapy for high-risk, node-negative breast cancer: Results from the GEICAM/2003-02 study

    Journal of Clinical Oncology

  2. PAM50 proliferation score as a predictor of weekly paclitaxel benefit in breast cancer

    Breast Cancer Research and Treatment, Vol. 138, Núm. 2, pp. 457-466

2012

  1. Spanish Society of Medical Oncology (SEOM) Cancer and Thrombosis Working Group

    Clinical and Translational Oncology

2010

  1. Current controversies in the management of breast cancer

    Clinical and Translational Oncology, Vol. 12, Núm. 4, pp. 278-286

  2. Erratum: Current controversies in the management of breast cancer (Clinical and Translational Oncology 12:4 (278-286))

    Clinical and Translational Oncology

  3. Molecular predictors of efficacy of adjuvant weekly paclitaxel in early breast cancer

    Breast Cancer Research and Treatment, Vol. 123, Núm. 1, pp. 149-157

2009

  1. Spanish Society of Medical Oncology consensus on the use of erythropoietic stimulating agents in anaemic cancer patients

    Clinical and Translational Oncology, Vol. 11, Núm. 11, pp. 727-736

2008

  1. Randomized phase 3 trial of fluorouracil, epirubicin, and cyclophosphamide alone or followed by paclitaxel for early breast cancer

    Journal of the National Cancer Institute, Vol. 100, Núm. 11, pp. 805-814

2007

  1. Current controversies in the management of early breast cancer

    Clinical and Translational Oncology, Vol. 9, Núm. 6, pp. 375-384